Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
The journey of CAR-T therapy in hematological malignancies
J Lu, G Jiang - Molecular cancer, 2022 - Springer
Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
[HTML][HTML] Extracellular vesicles: The next generation in gene therapy delivery
Extracellular vesicles (EVs) are esteemed as a promising delivery vehicle for various genetic
therapeutics. They are relatively inert, non-immunogenic, biodegradable, and …
therapeutics. They are relatively inert, non-immunogenic, biodegradable, and …
Potential solutions for manufacture of CAR T cells in cancer immunotherapy
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing
hurdles hamper its broad breakthrough. Although the first step towards automated …
hurdles hamper its broad breakthrough. Although the first step towards automated …
Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating
M Hamieh, J Mansilla-Soto, I Rivière, M Sadelain - Cancer Discovery, 2023 - AACR
The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion
Chimeric antigen receptor (CAR) T cells have not induced meaningful clinical responses in
solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during …
solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during …
CAR-T cell performance: how to improve their persistence?
G López-Cantillo, C Urueña, BA Camacho… - Frontiers in …, 2022 - frontiersin.org
Adoptive cell therapy with T cells reprogrammed to express chimeric antigen receptors (CAR-
T cells) has been highly successful in patients with hematological neoplasms. However, its …
T cells) has been highly successful in patients with hematological neoplasms. However, its …
Treatment strategies for patients with diffuse large B-cell lymphoma
S Poletto, M Novo, L Paruzzo, PMM Frascione… - Cancer treatment …, 2022 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …